Compare LYFT Inc (LYFT) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LYFT Inc vs Repligen Corporation Common Stock — how do they compare? LYFT Inc trades at $16.36 (market cap $6.20B), while Repligen Corporation Common Stock trades at $178.19 (market cap $11.14B). The key difference: Repligen Corporation Common Stock is the larger of the two by market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, LYFT Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold LYFT Inc for 48 Days and Repligen Corporation Common Stock for 0 Days on average.
| LYFT | RGEN | |
|---|---|---|
Market Cap | $6.20B | $11.14B |
Volume | 12,306,511 | 1,259,263 |
Sector | Technology | Health |
52-Week High | $24.57 | $194.57 |
52-Week Low | $12.65 | $102.87 |
Typical Hold Time | 48 Days | 0 Days |
Enterprise Value | $5.67B | $11.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lyft (LYFT) trades at $16.48, up 2.3% with a bullish technical signal. The stock shows strong fundamentals with a P/E of 2.38 and net income margin of 42.32%. Recent developments include European expansion and a $272.5M legal settlement. Cash flow improved significantly to $891M in 2025 from negative levels in prior years, while revenue grew to $6.32B.
Outlook remains positive with analyst consensus target of $18.07, though mixed earnings performance and regulatory risks persist. The stock offers value with low valuation multiples but faces competition and execution challenges in international markets. Recent technical indicators show overbought conditions near resistance at $17.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About LYFT Inc
Lyft is the second-largest ride-sharing service provider in the U.S., connecting riders and drivers over the Lyft app. Lyft recently entered the Canadian market in an effort to expand its market outside the U.S. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.
Read more on LYFT →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
